✦ LIBER ✦

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

✍ Scribed by Steigbigel, Roy T.; Cooper, David A.; Kumar, Princy N.; Eron, Joseph E.; Schechter, Mauro; Markowitz, Martin; Loutfy, Mona R.; Lennox, Jeffrey L.; Gatell, Jose M.; Rockstroh, Jurgen K.; Katlama, Christine; Yeni, Patrick; Lazzarin, Adriano; Clotet, Bonaventura; Zhao, Jing; Chen, Joshua; Ryan, Desmond M.; Rhodes, Rand R.; Killar, John A.; Gilde, Lucinda R.; Strohmaier, Kim M.; Meibohm, Anne R.; Miller, Michael D.; Hazuda, Daria J.; Nessly, Michael L.; DiNubile, Mark J.; Isaacs, Robin D.; Nguyen, Bach-Yen; Teppler, Hedy

Book ID: 120056513
Publisher: Massachusetts Medical Society
Year: 2008
Tongue: English
Weight: 324 KB
Volume: 359
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa0708975

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dual therapy with etravirine plus ralteg

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

✍ Monteiro, P.; Perez, I.; Laguno, M.; Martinez-Rebollar, M.; Gonzalez-Cordon, A.; 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 258 KB

Vicriviroc plus optimized background the

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

✍ Caseiro, Marcos M.; Nelson, Mark; Diaz, Ricardo S.; Gathe, Joseph; de Andrade Ne 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 929 KB

Optimizing antiretroviral therapy in ado

Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection

✍ Foster, Caroline ;Fidler, Sarah 📂 Article 📅 2010 🏛 Expert Reviews 🌐 English ⚖ 356 KB

Monitoring the emergence of resistance m

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: A follow-up study

✍ Passaes, Caroline Pereira Bittencourt; Guimarães, Monick Lindenmeyer; Cardoso, S 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

Cost-effectiveness of optimized backgrou

Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system

✍ Santiago Moreno; Juan González; Ingrid Lekander; Belén Martí; Itziar Oyagüez; Ra 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Viral rebound after switch to maraviroc/

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection

✍ Nozza, S.; Bigoloni, A.; Calcagno, A.; Galli, L.; Pignataro, A. R.; D'Avolio, A. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 113 KB